Table 3

Univariate and multivariate regression analyses of glibenclamide outcomes compared with placebo

Variable	Univariable regression analysis		Multivariable regression analysis
Variable	OR (95% CI)	P value	OR (95% CI)*	P value*
Primary outcome
SEBES (0–2) at 10 days after medication	2.06 (0.71 to 5.98)	0.184	4.66 (1.14 to 19.10)	0.032†
Secondary outcomes
mRS (0–2) at discharge	0.42 (0.13 to 1.37)	0.151	0.57 (0.16 to 2.07)	0.395
mRS (0–2) at 3 months	1.00 (0.35 to 2.85)	1.000	2.03 (0.53 to 7.71)	0.300
mRS (0–2) at 6 months	1.54 (0.54 to 4.42)	0.423	3.91 (0.92 to 16.56)	0.064
Modified Fisher scale (0–2) at 10 days after medication	2.50 (0.83 to 7.55)	0.104	3.94 (1.09 to 14.24)	0.037†
Adverse events
Death at discharge	1.56 (0.24 to 10.14)	0.641	1.33 (0.17 to 10.74)	0.787
Cerebral hernia	0.44 (0.10 to 1.98)	0.283	0.24 (0.04 to 1.33)	0.103
Cerebral infarction	0.68 (0.20 to 2.31)	0.538	0.39 (0.09 to 1.63)	0.197
Hydrocephalus	2.60 (0.84 to 8.07)	0.098	1.88 (0.51 to 7.01)	0.346
Pulmonary infection	2.75 (0.85 to 8.88)	0.091	2.27 (0.67 to 7.67)	0.186
Liver and kidney dysfunction	0.87 (0.30 to 2.47)	0.789	0.57 (0.18 to 1.88)	0.357
Vasospasm	2.06 (0.71 to 5.98)	0.184	1.95 (0.65 to 5.79)	0.231
Decompressive craniectomy at 10 days after medicine	0.48 (0.04 to 5.64)	0.560	0.32 (0.03 to 4.23)	0.389

*Data were adjusted for cerebrospinal fluid shunt during medication.
†On behalf of p<0.05.
mRS, modified Rankin Scale; SEBES, Subarachnoid Haemorrhage Early Brain Oedema Score.